Last updated: January 31, 2026
Executive Summary
TYLENOL W/ CODEINE NO. 4, a prescription opioid analgesic, is a Schedule III drug combining acetaminophen and codeine phosphate. Its market landscape is influenced by regulatory frameworks, public health policies, evolving prescribing practices, and competitive dynamics. This comprehensive analysis covers current market size, growth prospects, regulatory timelines, pricing factors, and competitive positioning, offering valuable insights for stakeholders and investors.
What Is TYLENOL W/ CODEINE NO. 4?
| Attribute |
Details |
| Active ingredients |
Acetaminophen (300 mg) + codeine phosphate (30 mg) |
| Schedule |
III (United States) |
| Indication |
Moderate to severe pain |
| Formulation |
Oral tablets |
Market Size and Current Market Position
Global and U.S. Market Overview
| Metric |
2022 Data |
Notes |
| Global analgesics market |
~$35 billion |
Expected CAGR 3-5% through 2027 |
| U.S. opioid analgesics segment |
~$12 billion |
Representing ~34% of total analgesics market |
| TYLENOL W/ CODEINE NO. 4 revenues (U.S.) |
Estimated ~$200 million |
Approximate, based on market share and sales data (IQVIA, 2022) |
Market Share
| Company |
Estimated Market Share |
Notes |
| Johnson & Johnson |
~30% |
Leading provider, via McNeil Products |
| Other niche providers |
~20% |
Smaller pharmaceutical firms |
| Hospital/institutional sales |
~50% |
Prescription and clinical use |
Regulatory and Policy Landscape
FDA Regulations
- Schedule III Classification (per DEA, 1970s)
- Labeling and prescribing restrictions introduced in 2020 to mitigate opioid abuse
- Abuse-deterrent formulations under development, impacting formulations and pricing
Legislative Initiatives
- The Opioid Crisis Response Act (2018): emphasizes prescribing limits and monitoring
- CDC Guidelines (2016): recommend cautious prescribing, affecting outpatient demand
- State-level legislative actions: restrictions varying by state, influencing market access
Impact on Market Dynamics
| Factor |
Effect |
| Increased regulation |
Reduced prescribing and sales volume |
| Prescription monitoring programs |
Market consolidation among providers |
| Abuse deterrence |
Potential premium for reformulated products |
Market Drivers and Limiters
Drivers
- Persistent demand for moderate pain relief in acute and chronic settings
- Physician prescribing practices favoring combination opioids over monotherapies
- Growing awareness of pain management needs pre-pandemic
- Supply chain stability due to strong manufacturing partnerships
Limiters
- Opioid epidemic and abuse concerns leading to regulatory crackdowns
- Shift towards non-opioid analgesics (NSAIDs, anticonvulsants, antidepressants)
- Public perception negatively impacting demand
- Pricing pressures from payers and insurers
Pricing and Reimbursement Dynamics
| Phase |
Details |
Impact on Financials |
| List Price (2022) |
~$10 per tablet |
Steady, but under pressure from generics & PBMs |
| Reimbursement |
Negotiated with insurers |
Margin variability |
| Out-of-pocket costs |
~$20–$30 per prescription |
Affected by formulary restrictions |
Reimbursement Policies
- Medicare/Medicaid restrict formularies
- Prior authorization often required
- Increasing emphasis on non-opioid alternatives
Competitive Landscape
Key Competitors
| Product |
Active Ingredients |
Market Position |
Notable Features |
| Tylenol with Codeine No. 4 |
Acetaminophen + codeine |
Market leader |
Established brand, broad prescriber base |
| Vicodin (Hydrocodone + acetaminophen) |
Hydrocodone + acetaminophen |
Similar market |
Slightly more potent, regulated under Schedule II |
| Percocet (Oxycodone + acetaminophen) |
Oxycodone + acetaminophen |
Higher potency |
More tightly regulated |
| Non-opioid alternatives |
NSAIDs, topical agents |
Growing segment |
No abuse potential |
Emerging Trends
- Transition to abuse-deterrent formulations
- Development of combination products with lower opioid doses
- Penetration of telemedicine reducing traditional prescription cycles
Financial Trajectory and Forecast
| Timeframe |
Revenue Projection |
Drivers |
Risks |
| 2023–2025 |
Slight decline, ~$150–180 million |
Regulatory tightening, shift to alternatives |
Potential litigation, generic price erosion |
| 2026–2030 |
Stabilization or slight rebound, ~$150 million |
Market niche, chronic pain management needs |
Ongoing opioid crisis reforms |
| Long-term (post-2030) |
Potential decline |
Obsolescence due to policy shifts |
Market exit, replaced by newer treatments |
Forecast Assumptions
- Continued regulatory pressure reducing prescriber volume by 5–10% annually
- Incremental market penetration of abuse-deterrent and non-opioid drugs
- Marginal price compression due to intensified generic competition
Comparison with Similar Medications
| Drug |
Schedule |
Active Ingredients |
Market Share (2022) |
Regulatory Status |
Price Range (per dose) |
| TYLENOL W/ CODEINE NO. 4 |
III |
Acetaminophen + codeine |
~1–2% of U.S. opioid market |
Prescribed, regulated |
$0.50–$1.00 |
| Vicodin |
II |
Hydrocodone + acetaminophen |
~30% of opioid market |
Stricter (Schedule II) |
$0.80–$1.20 |
| Percocet |
II |
Oxycodone + acetaminophen |
~15% |
Schedule II |
$1.00–$1.50 |
Regulatory and Market Considerations for Future Growth
- Potential Rescheduling: The DEA has considered reclassifying similar drugs, which could adversely impact availability.
- Abuse deterrent formulations: Increased adoption can justify higher pricing or market exclusivity.
- Alternative pain management therapies: New classes like nerve growth factor inhibitors may reduce reliance on opioids.
- Policy trends: Emphasis on safety may lead to further prescribing restrictions.
Key Market Risks and Opportunities
| Risks |
Opportunities |
| Regulatory tightening |
Niche positioning in severe pain segments |
| Demand decline |
Innovation in abuse-deterrent technology |
| Litigation expenses |
Potential premium pricing for reformulations |
| Public perception |
Emphasis on balanced pain management strategies |
Conclusion
TYLENOL W/ CODEINE NO. 4 faces a declining but still significant market driven by persistent demand in controlled medical settings. Regulatory pressures, public health policies, and market shifts towards non-opioid pain therapies are primary constraints shaping its economic trajectory. Although current revenues are modest compared to other analgesics, the product retains niche relevance, especially if reformulated to address abuse concerns. Future growth hinges on regulatory adaptability, innovation, and market acceptance of safer formulations.
Key Takeaways
- Market Share: Approximately 1–2% of the U.S. opioid analgesic market (~$12 billion).
- Revenue Trend: Expected to decline slightly through 2025, stabilizing thereafter.
- Regulatory Environment: Increasing restrictions under CDC guidelines and state laws.
- Pricing: Stable list prices, but margins under pressure from generics and payers.
- Competitive Position: Leader among combination opioids, but facing obsolescence risk due to policy shifts.
- Future Outlook: Focus area for reformulations with abuse-deterrent features; potential niche product, but long-term decline likely.
FAQs
1. How have recent regulatory changes impacted TYLENOL W/ CODEINE NO. 4 sales?
Recent regulations, including CDC prescribing guidelines and state-level restrictions, have reduced outpatient prescriptions, causing a decline in sales volume. Additionally, increased scrutiny has led to tighter prescribing limits.
2. What are the key factors determining the pricing strategy for TYLENOL W/ CODEINE NO. 4?
Pricing is influenced by manufacturer list prices, payer negotiations, formulary placement, competition from generics, and developments in abuse-deterrent formulations.
3. How does the market for TYLENOL W/ CODEINE NO. 4 compare to other opioid combination drugs?
It holds a smaller market share due to tighter scheduling (Schedule III) versus Schedule II drugs like Vicodin and Percocet, which generally command higher prices but face greater regulatory restrictions.
4. Is there long-term potential for TYLENOL W/ CODEINE NO. 4?
Long-term growth prospects are limited owing to regulatory pressures and market shifts towards non-opioid alternatives. However, niche applications remain viable if reformulated for abuse deterrence.
5. What are the competitive advantages of TYLENOL W/ CODEINE NO. 4?
Established brand recognition, broad prescriber acceptance, and a longstanding safety profile afford it a steady but shrinking market position, particularly if reformulated with abuse deterrent features.
References
[1] IQVIA (2022). Pharmaceutical Market Analysis.
[2] U.S. Drug Enforcement Administration (DEA). Controlled Substances Act. 1970.
[3] CDC (2016). Guideline for Prescribing Opioids for Chronic Pain.
[4] FDA (2020). Labeling and Regulatory Policies for Opioid Drugs.
[5] MarketWatch (2022). Analgesics Market Data.
